Here, you are invited to view (and share) stories of those struggling with the issues of terminal patient access, clinical trial enrollment inefficiency, and molecular medicine.  As an example, I offer a story of my grandfather’s, among others I have found.

To view more about this movement please read about the Petition or about the movement.

To Support, please share this video with everyone you know: http://www.youtube.com/watch?v=D_pr5sPYTG4&feature=player_profilepage

Terminal Patient Access

Didn’t know he had the option of Compassionate Use / Expanded Access

• Marshall Witt 1929-2007

Battled pharmaceuticals and the FDA to finally get approved for Expanded Access/Compassionate Use (the therapy he received later REVERSED his ALS progression — to see this skip to page 4 of the article; this is a testament that a little bit of hope may be all we need.)

• Joshua Thompson

Denied access to experimental therapies outside of clinical trials by the FDA

• [youtube=http://www.youtube.com/watch?v=RmlDsIJjQIw&feature=PlayList&p=2FB93FC117D22762&index=26]
• [youtube=http://www.youtube.com/watch?v=z0z1GagVGSk&feature=PlayList&p=2FB93FC117D22762&index=23&playnext=7&playnext_from=PL]
• [youtube=http://www.youtube.com/watch?v=XbsUr4s5zZ0&feature=PlayList&p=2FB93FC117D22762&index=22&playnext=6&playnext_from=PL]

Clinical Trials

• An estimated 80% of clinical trials in the United States are delayed because of  poor enrollment. Click me to view more.
• Didn’t know of her option for clinical trials:

“My daughter Janine Kresin died at the Univ of Ia Hosp and Clinics Sept 15, 2008 she had Non-Hodgkins Lymphoma. They offered her hope so she went for the Bone-marrow transplant. She went into seizures and was in ICU for a month before she died. I wish we would have been told about clinical trials.” – Mary Jane Baker

Personalized Diagnosis (at the molecular / genetic level)

• Dr. Bruce E. Johnson’s research on patients with various mutations in their Epidermal Growth Factor Receptors versus those without, and their response to EGFR inhibitors gefitinib and erlotinib (Iressa and Tarceva) – click me to read more.  For highlighted version, click me to read more.

• MDM2 is a known inhibitor of famous tumor suppressor protein p53.  If you have a mutation in both these genes in the same cell, a drug cocktail may be best for you.  For example, if you have an over expression of MDM2 and a dysfunctional p53 protein (you will only know if you have a protein and genetic mutation analysis), then it may be optimal for you to have monoclonal antibodies for MDM2 and gene therapy for p53 induced into the same cell at the same time.  For more, read ARF-MDM2-p53 pathway and MDM2-p53 interaction.
• Receptor thought to be important in Alzheimer’s progression — click me.
• A woman’s battle to live through breast cancer using PARP Inhibitors
• PARP Inhibitors

• Combining plasmodium proteins specific for liver cells with chemotherapeutic agent doxorubicin, UCI researchers are able to target specifically cells with this chemotherapeutic agents, effectively minimizing side effects felt by the heart and other organs that were previously affected.  Click me for more.

• Target of 3 to fight brain tumors (glioblastoma multiforme to be specific) – click me.
• Joseph Dougherty’s plea for a drug cocktail (among other things) for his brain tumor – click me.